Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT
暂无分享,去创建一个
M. Labopin | D. Blaise | A. Nagler | M. Mohty | Xiao-jun Huang | G. Ehninger | F. Ciceri | W. Arcese | B. Bruno | J. Maertens | B. Savani | J. Canaani | Z. Gülbaş | Y. Koç | J. Tischer | Y. Koc
[1] D. McKenna,et al. Impact of Graft-Recipient ABO Compatibility on Outcomes after Umbilical Cord Blood Transplant for Nonmalignant Disease. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] Xiao-jun Huang,et al. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? , 2016, Journal of Hematology & Oncology.
[3] M. Patnaik,et al. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA‐matched peripheral blood hematopoietic cell transplantation after reduced‐intensity conditioning , 2016, Transfusion.
[4] K. Byth,et al. Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] R. Vij,et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. , 2015, Blood.
[6] Yu Wang,et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets , 2015, Journal of Hematology & Oncology.
[7] J. Ward,et al. Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT , 2015, Bone Marrow Transplantation.
[8] Yu Wang,et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. , 2015, Blood.
[9] D. Porter,et al. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[11] A. Buser,et al. Impact of recipient ABH secretor status on outcome in minor ABO‐incompatible hematopoietic stem cell transplantation , 2015, Transfusion.
[12] A. Logan,et al. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] Daniel Wolff,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] M. Konopleva,et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] He Huang,et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. , 2014, Blood.
[16] A. Santoro,et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] K. Uchimaru,et al. Effect of ABO blood group incompatibility on the outcome of single-unit cord blood transplantation after myeloablative conditioning. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] J. Lundahl,et al. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] E. Gehrie,et al. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] A. Zachary,et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] S. Solomon,et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Nagler,et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. , 2013, Blood.
[23] F. Appelbaum. Pursuing the goal of a donor for everyone in need. , 2012, The New England journal of medicine.
[24] H. Tamaki,et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT , 2012, Bone Marrow Transplantation.
[25] M. Robin,et al. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] E. Shpall,et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT , 2010, Bone Marrow Transplantation.
[27] A. Madrigal,et al. Selection of adult unrelated hematopoietic stem cell donors: beyond HLA. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[28] B. Sandmaier,et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[29] M. Hirokawa,et al. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program , 2008, Haematologica.
[30] K. Sullivan,et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[32] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.